Remote monitoring for peritoneal dialysis: interview with Aly ElBadry, CEO of CloudCath

0
210


CloudCath, a San Francisco-based medical technology company, has created the CloudCath system, a remote control technology that provides clinicians with data on spent dialysis fluid from peritoneal dialysis patients at home. CloudCath joins the drain line of peritoneal dialysis systems and transmits data wirelessly to the cloud, with proprietary algorithms that highlight problems, such as infection, to doctors.

Currently, abnormalities in patients with peritoneal dialysis may not be marked in a timely manner. For example, patients are advised to check their dialysis using the “diary test,” so if the text of the diary cannot be read clearly through a dialysis bag, patients are advised to look for it. medical attention, as the dialysate may be infected. This is clearly not optimal and not just because printed newspapers are not as common as they used to be, which often results in a lost or late identification of potentially serious issues.

This latest technology aims to advance these problems and help increase the safety of peritoneal dialysis at home. CloudCath recently announced a partnership with American Renal Associates, an outpatient dialysis provider, with the goal of conducting a pre-market clinical study of its product in patients with peritoneal dialysis.

Medgadget He had the opportunity to speak with Aly ElBadry, CEO and co-founder of CloudCath, about the company’s technology and upcoming studio.

Conn Hastings, Medgadget: Please give us an overview of peritoneal dialysis and the patients who use it.

Aly ElBadry, CloudCath: Peritoneal dialysis (PD) removes waste from the blood when the kidneys are unable to do so. This procedure filters the blood in a different way than the more common blood filtration procedure known as hemodialysis. During the process, a cleansing fluid flows through a catheter into a part of the abdomen and the liner acts as a filter, removing waste from the blood. After a defined period of time, the fluid with the filtered waste comes out of your abdomen and is discarded. Patients who use PD should be able to care for themselves at home or have a reliable caregiver.

Medgadget: How common is it that patients can get dialysis at home? Is it usually self-administered or attended by a medical professional?

Aly ElBadry: Approximately 12.5% ​​of dialysis patients in the U.S. do it at home. In 2019, the White House announced an executive order proposing that 80% of new patients with end-stage renal disease (ESRD) be treated with kidney transplantation or home dialysis in 2025. Peritoneal dialysis is administered every night with the help of medical equipment, initiating a process called automatic cycle, while the patient sleeps. Patients can do peritoneal dialysis at home safely, he or she, sometimes helped by family or friends and other couples, but often independently.

Medgadget: How did the idea for the CloudCath system come about?

Aly ElBadry: The idea for CloudCath arose from our passion for chronic disease management and our interest in providing innovative software solutions to areas of unmet need. The co-founders, Eric Yu and I, have a history of merging these worlds and together we created this unique solution.

Medgadget: Please give us an overview of the system and how it works.

Aly ElBadry: The CloudCath device integrates seamlessly into the patient’s drainage line, monitoring dialysis fluid spent on each dialysis cycle by measuring and quantifying fluid properties remotely from patients ’homes. The data is transmitted to CloudCath’s cloud-based infrastructure in real time, where proprietary data algorithms notify healthcare providers when there is a possible escalation of complications. Through CloudCath’s remote monitoring platform, healthcare providers log in and access an unprecedented level of real-time data from their patients throughout treatment, aiding in the management of treatment decisions.

Medgadget: How do you think the system could change the way you manage dialysis? Do you anticipate a time when almost all patients will be able to perform peritoneal dialysis at home safely?

Aly ElBadry: Current standards of care are based on visual detection to identify the source of the infection, known as the “diary test.” If patients are unable to read a diary or print written text through a worn peritoneal dialysis collection bag, they are advised to seek medical attention, a strategy that involves late identification of the infection, and possible complications that can lead to hospitalization and potentially to a catheter removal procedure. , limiting the modality of treatment of the patient to the less convenient and more expensive option of hemodialysis.

CloudCath Medical Advisory Committee projects technology could lead to 75% reduction in hospitalizations caused by infections, which can save thousands of lives, depending on existing mortality rates, and reduce annual health care spending American up to $ 2.6 billion. In addition, in line with the current initiative, in order to increase the adoption of peritoneal dialysis, the safety and security of remote monitoring are key to the choice of peritoneal dialysis by additional patients.

Medgadget: Please give us an overview of your pre-marketing clinical study with American Renal Associates (ARA).

Aly ElBadry: The U.S.-based pre-marketing clinical trial will NOW evaluate the use of the CloudCath system by patients with PD. The final criteria for the clinical study of our work with NOW are critical to the production of clinical trials and will help drive future product development, regulatory activities, reimbursement strategy, and market adoption.

Medgadget: Do you have any other applications planned for the technology?

Aly ElBadry: CloudCath is developing a remote control platform. Although peritoneal dialysis is the first area of ​​unmet needs, we understand and are actively developing how CloudCath technology can provide remote control capabilities to control all catheter-based treatments.

Link: CloudCath Company Home …





Source link